Defining bacillus Calmette-Guerin refractory superficial bladder tumors

被引:138
作者
Herr, HW [1 ]
Dalbagni, G [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
关键词
bladder neoplasms; drug resistance; treatment failure; salvage therapy;
D O I
10.1097/01.ju.0000062605.92268.c6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We define bacillus Calmette-Guerin (BCG) refractory, high risk, superficial bladder cancer. Materials and Methods: A total of 93 patients received a 6-week induction course of BCG. They were evaluated for response after 3 and 6 months. Half of the patients received monthly maintenance BCG for 2 years and half did not. In both groups the initial responses to BCG at 3 and 6 months were correlated with subsequent tumor recurrence and progression. Results: Of the 93 cases 57% were negative for tumor at 3 months and 43% had residual tumor resected. At 6 months 80% of the patients were tumor-free and 20% had persistent or recurrent tumor. Maintenance BCG did not decrease tumor recurrence further than induction BCG. Subsequent tumor-free interval during 24 months of followup were best predicted by response to BCG after 6 months. Conclusions: A minimum treatment and followup time of 6 months is required to identify high risk, superficial bladder tumors as truly BCG refractory.
引用
收藏
页码:1706 / 1708
页数:3
相关论文
共 16 条
[1]   A PROSPECTIVE RANDOMIZED TRIAL OF MAINTENANCE VERSUS NONMAINTENANCE INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY OF SUPERFICIAL BLADDER-CANCER [J].
BADALAMENT, RA ;
HERR, HW ;
WONG, GY ;
GNECCO, C ;
PINSKY, CM ;
WHITMORE, WF ;
FAIR, WR ;
OETTGEN, HF .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (03) :441-449
[2]   Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder [J].
Dalbagni, G ;
Russo, P ;
Sheinfeld, J ;
Mazumdar, M ;
Tong, W ;
Rabbani, F ;
Donat, MS ;
Herr, HW ;
Sogani, P ;
dePalma, D ;
Bojorin, D .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) :3193-3198
[3]   A RANDOMIZED CONTROLLED-STUDY OF INTRAVESICAL INTERFERON-ALPHA-2B IN CARCINOMA INSITU OF THE BLADDER [J].
GLASHAN, RW .
JOURNAL OF UROLOGY, 1990, 144 (03) :658-661
[4]   Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder [J].
Greenberg, RE ;
Bahnson, RR ;
Wood, D ;
Childs, SJ ;
Bellingham, C ;
Edson, M ;
Bamberger, MH ;
Steinberg, GD ;
Israel, M ;
Sweatman, T ;
Giantonio, B ;
ODwyer, PJ .
UROLOGY, 1997, 49 (03) :471-475
[5]   SUPERFICIAL BLADDER-CANCER TREATED WITH BACILLUS CALMETTE-GUERIN - A MULTIVARIATE-ANALYSIS OF FACTORS AFFECTING TUMOR PROGRESSION [J].
HERR, HW ;
BADALAMENT, RA ;
AMATO, DA ;
LAUDONE, VP ;
FAIR, WR ;
WHITMORE, WF .
JOURNAL OF UROLOGY, 1989, 141 (01) :22-29
[6]   Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? [J].
Herr, HW ;
Sogani, PC .
JOURNAL OF UROLOGY, 2001, 166 (04) :1296-1299
[7]   The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder [J].
Kim, JC ;
Steinberg, GD .
JOURNAL OF UROLOGY, 2001, 165 (03) :745-756
[8]   MANAGEMENT OF LOCAL BACILLUS CALMETTE-GUERIN FAILURES IN SUPERFICIAL BLADDER-CANCER [J].
KLEIN, EA ;
ROGATKO, A ;
HERR, HW .
JOURNAL OF UROLOGY, 1992, 147 (03) :601-605
[9]   Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: An investigational approach [J].
Luciani, LG ;
Neulander, E ;
Murphy, WM ;
Wajsman, Z .
UROLOGY, 2001, 58 (03) :376-379
[10]   ANALYSIS OF EARLY FAILURES AFTER INTRAVESICAL INSTILLATION THERAPY WITH BACILLE CALMETTE-GUERIN FOR CARCINOMA IN-SITU OF THE BLADDER [J].
MERZ, VW ;
MARTH, D ;
KRAFT, R ;
ACKERMANN, DK ;
ZINGG, EJ ;
STUDER, UE .
BRITISH JOURNAL OF UROLOGY, 1995, 75 (02) :180-184